Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 30;13(1):77.
doi: 10.3390/cancers13010077.

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Ping Gong  1   2 , Yifan Wang  2 , Pengfei Zhang  1 , Zhaogang Yang  2 , Weiye Deng  2 , Zhihong Sun  1   3 , Mingming Yang  2 , Xuefeng Li  2 , Gongcheng Ma  1 , Guanjun Deng  1 , Shiyan Dong  2 , Lintao Cai  1 , Wen Jiang  2
Affiliations
Review

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Ping Gong et al. Cancers (Basel). .

Abstract

Despite the advances in surface bioconjugation of synthetic nanoparticles for targeted drug delivery, simple biological functionalization is still insufficient to replicate complex intercellular interactions naturally. Therefore, these foreign nanoparticles are inevitably exposed to the immune system, which results in phagocytosis by the reticuloendothelial system and thus, loss of their biological significance. Immunocyte membranes play a key role in intercellular interactions, and can protect foreign nanomaterials as a natural barrier. Therefore, biomimetic nanotechnology based on cell membranes has developed rapidly in recent years. This paper summarizes the development of immunocyte membrane-coated nanoparticles in the immunotherapy of tumors. We will introduce several immunocyte membrane-coated nanocarriers and review the challenges to their large-scale preparation and application.

Keywords: T-cell; biomimicry; cancer immunotherapy; dendritic cell; immunocyte membrane-coated nanoparticles; macrophage; natural killer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Schematic showing the formation of hNVs and the mechanism by which hNVs amplify macrophage immune responses against cancer recurrence and metastasis [83].
Figure 2
Figure 2
Schematic illustration of NK cell membrane-cloaked nanoparticles for PDT-enhanced cell membrane immunotherapy [109].
Figure 3
Figure 3
Schematic illustration of the preparation of intelligent dendritic cells (iDCs) and the mechanism of synergy between iDCs and mild photothermal-immunotherapy.
See this image and copyright information in PMC

References

    1. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat. Rev. Cancer. 2011;11:805–812. doi: 10.1038/nrc3153. - DOI - PMC - PubMed
    1. Finck A., Gill S.I., June C.H. Cancer immunotherapy comes of age and looks for maturity. Nat. Commun. 2020;11:1–4. doi: 10.1038/s41467-020-17140-5. - DOI - PMC - PubMed
    1. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489. doi: 10.1038/nature10673. - DOI - PMC - PubMed
    1. Policard A. Cell Membranes and Their Role in the Cell Function. Pathol. Biol. 1968;16:973–977. - PubMed
    1. Bentrup F.W. Function of Cell Membranes in Cytomorphogenesis. Ber. Deut. Bot. Ges. 1968;81:311–314.

LinkOut - more resources